心脏瘤学中的药物预防:从长椅到床边
Ashot A Avagimyan1, Nana Pogosova2,3, Federica Fogacci4
1Department of Internal Diseases Propedeutics, Yerevan State Medical University, Yerevan, 0025, Armenia. ashot.avagimyan@meduni.am.
癌症疗法,如人环素可以伤害心脏 (与癌症治疗相关的心血管毒性). 本综述探讨了预防这种心脏损伤的方法,强调了新的潜在治疗方法,如SGLT2抑制剂.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学 是一个学科.
背景情况:
- 癌症存活率有所改善,但像 antracyclines 这样的治疗方法会导致显著的心血管风险,称为癌症治疗相关心血管毒性 (CTR-CVT).
- 缓解CTR-CVT对于维持患者的生活质量和治疗坚持至关重要.
研究的目的:
- 审查和整合关于预防和管理CTR-CVT的策略的证据,特别是与antracycline化疗相关的策略.
- 评估各种药理干预措施在癌症治疗期间保持心血管功能的有效性.
主要方法:
- 对针对CTR-CVT的心脏保护策略的临床前和临床研究进行系统审查.
- 从研究神经激素抑制剂,阿尔多激素对抗剂,他类药物和SGLT2抑制剂的试验中分析数据.
主要成果:
- 神经激素抑制剂 (ACEi,ARBs,βB) 是基本的,但结果各不相同; 卡维迪洛尔提供抗氧化功效. 萨库比特里尔/瓦尔萨坦 (ARNI) 在保持LVEF方面表现有前途,但具有低血压风险.
- 阿尔多斯特对抗剂,如螺旋乳,可以保持LVEF和透缩功能. 类固醇药的有效性是相互矛盾的,一些试验显示有好处,而另一些则没有.
- 新出现的数据表明,-葡萄糖共运输体-2 抑制剂 (SGLT2i) 通过代谢调节,抗炎和抗氧化作用提供心脏保护.
结论:
- 在了解CTR-CVT病理生理学和风险分层方面存在重大差距.
- 未来的研究应该专注于个性化医疗,动态风险评估,并探索心脏代谢功能障碍.
- SGLT2 抑制剂是预防CTR-CVT的一个有希望的前沿,需要在临床试验中进一步验证.
更多相关视频
08:21Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
相关概念视频
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Coronary Artery Disease IV: Preventive Measures
Cardiopulmonary Resuscitation IV: Pharmacological Management
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cardiovascular Drugs: Classification based on Therapeutic Indications
